MetLife Investment Management’s Cytosorbents Corp CTSO Stock Holding History

MetLife Investment Management’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,424	Closed	-$125K	–	2508
2021 Q3	$125K	Buy	+15,424	New	+$125K	﹤0.01%	2342
2021 Q2	–	Sell	-17,682	Closed	-$153K	–	2448
2021 Q1	$153K	Buy	17,682 +2,706	+18%	+$25.8K	﹤0.01%	2180
2020 Q4	$119K	Hold	14,976	–	–	﹤0.01%	2207
2020 Q3	$119K	Hold	14,976	–	–	﹤0.01%	2132
2020 Q2	$148K	Buy	+14,976	New	+$138K	﹤0.01%	2061
2019 Q3	–	Sell	-14,785	Closed	-$97.7K	–	2343
2019 Q2	$97.7K	Hold	14,785	–	–	﹤0.01%	2376
2019 Q1	$112K	Hold	14,785	–	–	﹤0.01%	2280
2018 Q4	$119K	Hold	14,785	–	–	﹤0.01%	2208
2018 Q3	$191K	Hold	14,785	–	–	﹤0.01%	2113
2018 Q2	$169K	Buy	+14,785	New	+$140K	﹤0.01%	1994

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's CTSO Position: Q4 2021 in Review

MetLife Investment Management sold out of Cytosorbents Corp (CTSO) in Q4 2021, closing a stake of 15,424 shares — an estimated $125K sold.

MetLife Investment Management first reported a position in CTSO in Q2 2018 and held it in 10 quarters. The position peaked at $191K in Q3 2018. 91 funds tracked by Wall St. Rank hold CTSO as of Q4 2021.

MetLife Investment Management reported no remaining Cytosorbents Corp position as of Q4 2021 after selling out during the quarter.
MetLife Investment Management sold 15,424 Cytosorbents Corp shares in Q4 2021, an estimated $125K.
MetLife Investment Management first reported a position in Cytosorbents Corp in Q2 2018 and held it in 10 quarters.
MetLife Investment Management's Cytosorbents Corp position peaked at $191K in Q3 2018.
91 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.